Compare ASML Holding NV (ASML) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ASML Holding NV vs Sana Biotechnology Inc — how do they compare? ASML Holding NV trades at $1,821.48 (market cap $689.17B), while Sana Biotechnology Inc trades at $3.75 (market cap $1.13B). The key difference: ASML Holding NV is far larger — about 609.9× Sana Biotechnology Inc's market cap, and ASML Holding NV pays a 0.5% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ASML | SANA | |
|---|---|---|
Market Cap | $689.17B | $1.13B |
Sector | Technology | Health |
52-Week High | $1.99K | $5.92 |
52-Week Low | $725.85 | $2.68 |
Enterprise Value | $682.70B | $1.05B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASML trades at $1,733.48, down 0.43% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a 29.41% net income margin and robust revenue growth to $32.67B in 2025. Recent earnings beats in Q1 and Q2 2026, coupled with a consensus price target of $2,390, highlight positive momentum, though high valuation ratios like a P/E of 61.28 pose risks.
Outlook remains favorable due to AI-driven semiconductor demand, but investors face risks from geopolitical tensions with China and stretched valuations. Analyst consensus is strongly bullish with 57% buy ratings, supporting potential upside, though monitoring competitive threats and earnings consistency is crucial for sustained growth.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
